Neurological Disorders

Neuropathic pain drug pipeline

  • ICD-11 MG30.5
  • MeSH D009437

2 compounds from 2 companies are in active clinical development for neuropathic pain, including 1 at Phase 3 or beyond.

2Compounds
2Companies
1Phase 3+
79Trials recruiting

Mechanisms: Natural product (1) · Small molecule (1)

Pipeline data compiled September 2026 · every fact sourced.

Upcoming readouts & recent results

  • 2021-09-16ReportedVixotrigineTopline datamixedNCT03339336

    Phase 2 CONVEY topline in painful small fiber neuropathy: vixotrigine 200 mg BID met the primary endpoint (change from baseline in average daily pain at Week 12 of the double-blind period, p=0.050 vs placebo); 350 mg BID did not (p=0.70).

See the full catalyst calendar →

Compounds in development (2)

CompoundCompanyPhaseStatusMechanism
AP707Apurano Pharmaceuticals GmbHPhase 3UnknownCB1 Partial agonist
VixotrigineBiogenDiscontinuedDiscontinuedNav1.7 Inhibitor

Trials recruiting now (73)

73 drug-interventional neuropathic pain trials recruiting now, of 629 registered interventional trials. Browse all on ClinicalTrials.gov →

Showing the 12 most advanced of 73 recruiting drug trials · see all on ClinicalTrials.gov →

Frequently asked

How many drugs are in development for neuropathic pain?
2 compounds from 2 companies are in active clinical development for neuropathic pain, including 1 at Phase 3 or beyond.
Which neuropathic pain drugs are in Phase 3?
Phase 3 (or later) programs for neuropathic pain include AP707.
How many clinical trials are recruiting for neuropathic pain?
73 drug-interventional neuropathic pain trials are currently recruiting participants, out of 629 registered interventional trials.